摘要
目的:探讨多西他赛联合顺铂化疗同步三维适形放射治疗(3-DCRT)治疗局部晚期非小细胞肺癌的近期疗效、近远期毒副反应、生存期及生活质量。方法:75例经病理或组织细胞学确诊的局部晚期非小细胞肺癌患者(ⅢA或ⅢB)随机分为新辅助化疗+放疗(诱导组)和同期放化疗(同步组)两组。两组病例均采用3-DCRT计划,照射剂量70～80Gy,2Gy/次,5次/周。同步组:39例,多西他赛20mg/m2,静脉滴入,d1,顺铂30mg/m2,静脉滴入,d1,在放射治疗开始时同步进行,1次/周,用7～8次。诱导组:36例,多西他赛60mg/m2,静脉滴入,d1,顺铂30mg/m2,静脉滴入,d1～d3,每3周1次,2个周期后行3-DCRT。结果:同步组和诱导组的总有效率分别为69.23%(27/39)和41.67%(15/36),差异有统计学意义,P<0.05;中位生存时间分别为22.5和19.3个月;1年总生存率分别为69.23%和52.78%,P=0.14;1年局部控制率分别为58.97%和38.89%,P=0.08。结论:3-DCRT联合周剂量多西他赛加顺铂同步治疗局部晚期非小细胞肺癌近期疗效较好,能明显提高患者的生活质量,不良反应均能耐受。
OBJECTIVE：To evaluate the efficacy of docetaxel plus cisplatin chemotherapy with concurrent three dimensional radiotherapy（3-DCRT）in patients with locally advanced non-small cell lung caner（NSCLC）.METHODS：A total of 75 patients with locally advanced lung cancer were divided randomly into the induction group（36 cases）and the concurrent group（39 cases）.Both groups received 3-DCRT radiotherapy with a total dose of 70-80 Gy,2 Gy/f,5 times per week.The patients in the concurrent group were treated with docetaxel（20 mg/m2）d1 and cisplatin（30 mg/m2）d1 weekly for 7～8 cycles.The patients in the induction group were treated with docetaxel（60 mg/m2）d1 and cisplatin（30 mg/m2）d1-d3.The cycle was repeated every 21 days.Radiotherapy was given after 2 cycles of chemotherapy.RESULTS：The response rates of the concurrent group and the induction group were 69.23%（27/39）and 41.67%（15/36）,respectively,with a statistical significance（P0.05）.Median survival time was 22.5 months in the concurrent group and 19.3 months in the induction group;The one-year survival rate was 69.23% and 52.78%,respectively（P=0.14）;The one-year local control rate was 58.97% and 38.89%（P=0.08）.CONCLUSION：3-DCRT combined with concurrent docetaxel plus cisplatin chemotherapy is well tolerated and can improve the quality of life in most patients with locally advanced NSCLC.
出处
《中华肿瘤防治杂志》
CAS
2010年第9期699-702,共4页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺/放射疗法
癌
非小细胞肺/药物疗法
治疗结果
carcinoma
non-small cell lung/radiotherapy
carcinoma
non-small cell lung/drug therapy
treatment outcome
